Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

17 Aug 2010

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

17 Aug 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

EntreMed, Inc.,a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.

16 Aug 2010

Scientists use PCT technique to understand physical effects of compression on macromolecules

Scientists are turning to a decades-old technique to better understand the physical effects of compression on macromolecules and how it might impact their research in proteomics, mass spectrometry, protein extraction, and tissue investigations, reports Genetic Engineering & Biotechnology News.

16 Aug 2010

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Susan G. Komen for the Cure and the Ovarian Cancer National Alliance today urged the U.S. Food and Drug Administration to continue to allow the use of the drug bevacizumab, commonly known as Avastin, for metastatic breast cancer patients, noting that it is effective for some patients and warning of a chilling effect on new drug development if approval is withdrawn.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Scientists develop new metabolite analysis technique for accurate ovarian cancer detection

Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

12 Aug 2010

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Myriad Genetics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2010.

11 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Telik reports net loss of $4.9 million for second-quarter 2010

Telik, Inc. today reported a net loss of $4.9 million, or $0.09 per share, for the second quarter ended June 30, 2010, compared with a net loss of $5.7 million, or $0.11 per share, for the comparable period in 2009.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period and fiscal year ended June 30, 2010.

5 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

EntreMed second quarter 2010 net loss increases to $0.62 per share

Scientists use PCT technique to understand physical effects of compression on macromolecules

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Study finds Olaparib can reduce tumor size in ovarian cancer women

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Scientists develop new metabolite analysis technique for accurate ovarian cancer detection

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Telik reports net loss of $4.9 million for second-quarter 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in